5 天
Clinical Trials Arena on MSNRactigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancerThe company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene ... via intravesical instillation using Ractigen's proprietary LiCO™ delivery technology, RAG-01 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果